What The FDA's Psychedelic Drug Focus Means For Classic Psychedelic Development
A conversation between Psychedelic Alpha Founder Josh Hardman and Clinical Leader Executive Editor Abby Proch
With an addition to its website — a psychedelic resource page — it seems the FDA is increasingly interested in psychedelic drug development. But even with the growing regulatory interest, sponsors advancing classic psychedelics still face complicated clinical, regulatory, and commercial questions.
Josh Hardman, founder of Psychedelic Alpha, has spent nearly a decade tracking that landscape, including policy shifts, agency actions, trial design, access, and care delivery. In this interview, he discusses what FDA’s growing engagement does and does not resolve for companies developing treatments that rely on supervised administration, patient support, and psychoactive effects.
Taken alongside Joseph Tucker’s discussion of Enveric’s non-hallucinogenic neuroplastogen approach, Hardman’s perspective broadens the conversation by asking what it may take for regulators, sponsors, clinicians, and healthcare systems to accommodate the psychedelic experience rather than engineer around it.
Clinical Leader: The April 2026 Executive Order on psychedelic drug development signaled growing federal interest in accelerating neuropsychiatric innovation. How does the FDA's psychedelic drug development resource page build on that momentum, and does it represent a more concrete regulatory signal for classic psychedelics?
Josh Hardman: The new resource page brings together the agency’s finalized clinical trial guidance, issued priority vouchers, federal collaboration, public engagement, and other information and actions in one place. The existence of the webpage itself, and the fact that it featured atop the homepage of FDA’s website for some time, makes it clear that psychedelics are no longer treated as an isolated or speculative area of drug development.
Despite these policy and regulatory developments, what fundamental scientific, clinical, and regulatory challenges remain unchanged for classic psychedelic therapies?
There are still unresolved questions around dose optimization, retreatment, generalizability of results, rare or delayed adverse events, and the treatment of patients with medical or psychiatric comorbidities. We will likely continue to gather data that begins to answer these questions in the post-marketing environment.
There are also many regulatory questions that remain unanswered, including the constraints that agencies like FDA and DEA will place around the use of these drugs and their legal status, respectively. Commercially, reimbursement from private and public payors remains the most significant known unknown.
Classic psychedelics are generally being developed within treatment models that combine a psychoactive drug experience with preparation, clinical supervision, and post-session support. Why is that model important, and what distinguishes it from conventional drug development?
What distinguishes this from a great deal of conventional drug development is that the drug is expected to be delivered in a supervised model, as opposed to being dispensed for at-home use. While that sets psychedelic-based treatments apart from many others, we can look to approved medications like esketamine (Spravato) as an example of a drug that is delivered in a monitored context. Still, there is a great deal of debate within the psychedelics field around how much support should be given.
For sponsors, it is important that they characterize the type of non-drug support delivered in the studies, which could ultimately appear on a label, if approved. This is just one of the reasons why many psychedelic drug developers have sought to minimize the quantity and intensity of non-drug support delivered in their studies, including during dosing sessions.
How central is the acute psychedelic experience to the therapeutic potential of classic psychedelics? What does the current evidence suggest about the relationship between subjective effects and clinical outcomes?
This remains an empirical question. There are some data suggesting that the subjective experience is a driver of efficacy, while other early-stage research has suggested that it may not be necessary. There are myriad drug developers working to advance so-called non-hallucinogenic psychedelics, or neuroplastogens, which aim to engineer out the subjective experience while retaining clinical benefit. The vast majority of this work is not yet in humans.
Do you expect classic psychedelic therapies to face distinct regulatory requirements because of their acute psychoactive effects, the need for supervised administration, and the broader treatment infrastructure involved?
Approvals of the latest-stage psychedelic candidates will surely have REMS attached. This would likely feature stipulations around minimum monitoring durations and the availability of healthcare professionals, as well as other elements of the treatment delivery and location. One could look to the Spravato REMS for an idea of what this could look like, though classical psychedelics would feature longer minimum monitoring periods than esketamine’s 2 hours.
Beyond demonstrating clinical efficacy, what evidence will be needed to show that classic psychedelic therapies can be implemented safely and practically within the healthcare system?
While it appears to be less of a focus for the FDA’s Division of Psychiatry of late, characterizing durability is important for payors and, as such, will inform the practicality and scalability of any approved medicines.
Looking ahead, what specific actions from the FDA, DEA, NIH, Department of Defense, or other federal agencies would most help translate current policy interest into meaningful clinical progress for classic psychedelics?
As the first psychedelic candidates approach potential approvals, focus now turns to ensuring their scalability and accessibility. I hope to see continued engagement from CMS/CMMI, which could lead to the development of bundled payment models for psychedelic-based treatments. There are also plenty of actions the DEA could take to streamline psychedelic research and, if approved, access.
Funding bodies like the NIH and ARPA-H might also consider supporting research into different models of psychedelic care delivery, including group sessions, that might be more scalable and accessible.
About The Expert:
Josh Hardman is the founder of Psychedelic Alpha, a resource covering psychedelic policy, research, and drug development. For nearly a decade, he's methodically tracked the sector and has become one of the most trusted independent voices in the space.